Fenwick Represents Gritstone bio in its $32.5 Million Public Offering

Fenwick represented Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, in its $32.5 million underwritten public offering of its common stock and pre-funded warrants in lieu of common stock and accompanying warrants to purchase common stock (or pre-funded warrants), before deducting underwriting discounts and commissions and offering expenses. One share of common stock (or pre-funded warrant) and accompanying warrant was sold at a combined public offer price of $1.50 per unit (or $1.4999 for the pre-funded warrants). The accompanying warrants have an exercise price of $1.65 per share and are exercisable for twelve months from issuance.

TD Cowen and Evercore ISI acted as the joint book-running managers for the offering. More information can be obtained from Gritstone bio’s announcement.

The Fenwick transaction team included corporate partners Robert Freedman and Ryan Mitteness, counsel Chelsea Anderson and associates Beth Clarke, Lindsey Macalalad and Leya Maloney.